SCHEMBL4347315

SCHEMBL4347315

O=C(Nc1ccccc1)N(S)c1cccc(Cl)c1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 6/20 0.49
ERBB2 P04626 5/20 0.49
MAPT P10636 5/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
ALDH1A1 P00352 3/20 0.43
ALOX15 P16050 2/20 0.43
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
KLKB1 P03952 1/20 0.43
PLAU P00749 2/20 0.40
PLAT P00750 2/20 0.40
F2 P00734 1/20 0.40
F10 P00742 1/20 0.40
NPSR1 Q6W5P4 2/20 0.40
HTT P42858 1/20 0.40
KDM4E B2RXH2 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4343809 0.90 TSHR (0.47) EGFRERBB2MAPTNPC1RAB9A
SCHEMBL4354035 0.86 MEN1 (0.42) MAPTRAB9AMEN1KMT2AALDH1A1
SCHEMBL4353671 0.84 P2RX1 (0.49) NPC1RAB9AKLKB1
SCHEMBL4346853 0.83 STK39 (0.51) EGFRERBB2MAPTNPC1RAB9A
SCHEMBL4347354 0.82 KMT2A (0.46) EGFRERBB2MAPTNPC1RAB9A
SCHEMBL4346890 0.78 KMT2A (0.43) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL4351896 0.78 MAPT (0.48) EGFRERBB2MAPTNPC1RAB9A
SCHEMBL4349377 0.77 EGFR (0.41) EGFRERBB2MAPTNPC1RAB9A
SCHEMBL4356059 0.77 NPC1 (0.50) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4341634 0.77 ALDH1A1 (0.40) EGFRALDH1A1ALOX15LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 EGFR 1661/4885ERBB2 1297/4885MAPT 4439/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 EGFR 1635/4885ERBB2 1020/4885MAPT 4184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.